Cargando…
An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design
The 2013–2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucl...
Autores principales: | Herst, C.V., Burkholz, S., Sidney, J., Sette, A., Harris, P.E., Massey, S., Brasel, T., Cunha-Neto, E., Rosa, D.S., Chao, W.C.H., Carback, R., Hodge, T., Wang, L., Ciotlos, S., Lloyd, P., Rubsamen, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186210/ https://www.ncbi.nlm.nih.gov/pubmed/32418793 http://dx.doi.org/10.1016/j.vaccine.2020.04.034 |
Ejemplares similares
-
A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
por: Harris, Paul E., et al.
Publicado: (2021) -
Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome
por: Rubsamen, Reid, et al.
Publicado: (2020) -
Paired SARS-CoV-2 spike protein mutations observed during ongoing SARS-CoV-2 viral transfer from humans to minks and back to humans
por: Burkholz, Scott, et al.
Publicado: (2021) -
Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study
por: Burkholz, Scott R., et al.
Publicado: (2023) -
An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer Modeling
por: Cunha-Neto, Edecio, et al.
Publicado: (2017)